{"count": 2, "results": [{"_id": "36648216", "pmid": 36648216, "pmcid": "PMC9986389", "title": "Frequency and characteristics of diabetes in lipodystrophies and insulin receptoropathies compared with type 1 and type 2: results from the multicenter DPV registry", "journal": "Endocr Connect", "authors": ["Kamrath C", "Eckert A", "Rami-Merhar B", "Kummer S", "Wabitsch M", "Laubner K", "Kopp F", "Müther S", "Mühldorfer S", "Holl RW"], "date": "2023-02-20T00:00:00Z", "doi": "10.1530/EC-22-0333", "meta_date_publication": "2023 Mar 1", "meta_volume": "12", "meta_issue": "3", "meta_pages": "", "score": 50263.59, "text_hl": "A total of 38 @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Pseudoacromegaly_with_Severe_Insulin_Resistance</m> @DISEASE_MESH:C566531 @@@SIRS@@@ (57%) received @GENE_INS @GENE_3630 @@@insulin@@@ and 34 (51%) other antidiabetics, mostly @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Kamrath C, Eckert A, Rami-Merhar B, Kummer S, Wabitsch M, Laubner K, Kopp F, Müther S, Mühldorfer S, Holl RW. Frequency and characteristics of diabetes in lipodystrophies and insulin receptoropathies compared with type 1 and type 2: results from the multicenter DPV registry Endocr Connect. 2023 Mar 1;12(3):. PMID: 36648216", "BibTeX": "@article{36648216, title={Frequency and characteristics of diabetes in lipodystrophies and insulin receptoropathies compared with type 1 and type 2: results from the multicenter DPV registry}, author={Kamrath C and Eckert A and Rami-Merhar B and Kummer S and Wabitsch M and Laubner K and Kopp F and Müther S and Mühldorfer S and Holl RW}, journal={Endocr Connect}, volume={12}, number={3}}"}}, {"_id": "36457559", "pmid": 36457559, "pmcid": "PMC9705576", "title": "Diabetes duration and types of diabetes treatment in data-driven clusters of patients with diabetes", "journal": "Front Endocrinol (Lausanne)", "authors": ["Zhang J", "Deng Y", "Wan Y", "Wang J", "Xu J"], "date": "2022-11-15T00:00:00Z", "doi": "10.3389/fendo.2022.994836", "meta_date_publication": "2022", "meta_volume": "13", "meta_issue": "", "meta_pages": "994836", "score": 50259.2, "text_hl": "Among the non-@GENE_INS @GENE_3630 @@@insulin@@@ hypoglycemic drug options, @<m>DISEASE_Pseudoacromegaly_with_Severe_Insulin_Resistance</m> @DISEASE_MESH:C566531 @@@SIRD@@@ had higher rates of receiving @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, @GENE_SI @GENE_6476 @@@alpha-glucosidase@@@ inhibitor (AGI), and @GENE_GCG @GENE_2641 @@@glucagon-like peptide-1@@@ drug; the @DISEASE_Maturity_Onset_Diabetes_of_the_Young_Type_1 @DISEASE_MESH:C565101 @@@MOD@@@ and @DISEASE_Maturity_Onset_Diabetes_of_the_Young_Type_1 @DISEASE_MESH:C565101 @@@MARD@@@ groups both received @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, AGI and sodium-glucose cotransporter 2 inhibitor (SGLT-2i) drug ratio was higher. ", "citations": {"NLM": "Zhang J, Deng Y, Wan Y, Wang J, Xu J. Diabetes duration and types of diabetes treatment in data-driven clusters of patients with diabetes Front Endocrinol (Lausanne). 2022;13():994836. PMID: 36457559", "BibTeX": "@article{36457559, title={Diabetes duration and types of diabetes treatment in data-driven clusters of patients with diabetes}, author={Zhang J and Deng Y and Wan Y and Wang J and Xu J}, journal={Front Endocrinol (Lausanne)}, volume={13}, pages={994836}}"}}]}